Healthcare of Ontario Pension Plan Trust Fund Takes Position in Arcutis Biotherapeutics, Inc. $ARQT

Posted by Stanley Muller on Jun 16th, 2026

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 900,000 shares of the company’s stock, valued at approximately $26,136,000.

A number of other large investors also recently modified their holdings of ARQT. Focus Partners Wealth raised its position in Arcutis Biotherapeutics by 0.8% during the 3rd quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock worth $1,237,000 after purchasing an additional 490 shares during the last quarter. Schroder Investment Management Group raised its position in Arcutis Biotherapeutics by 1.1% during the 4th quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock worth $1,604,000 after purchasing an additional 594 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Arcutis Biotherapeutics by 124.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after purchasing an additional 698 shares during the last quarter. Entropy Technologies LP raised its position in Arcutis Biotherapeutics by 7.0% during the 4th quarter. Entropy Technologies LP now owns 12,144 shares of the company’s stock worth $353,000 after purchasing an additional 792 shares during the last quarter. Finally, DNB Asset Management AS raised its position in Arcutis Biotherapeutics by 3.0% during the 4th quarter. DNB Asset Management AS now owns 27,786 shares of the company’s stock worth $807,000 after purchasing an additional 802 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wall Street Zen lowered Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Mizuho lowered their target price on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, May 7th. HC Wainwright raised their target price on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Guggenheim raised their target price on Arcutis Biotherapeutics from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $34.00.

Read Our Latest Analysis on Arcutis Biotherapeutics

Arcutis Biotherapeutics Stock Performance

Shares of Arcutis Biotherapeutics stock opened at $25.58 on Tuesday. The company has a current ratio of 2.68, a quick ratio of 2.46 and a debt-to-equity ratio of 0.54. The business has a 50-day moving average price of $22.58 and a two-hundred day moving average price of $25.22. Arcutis Biotherapeutics, Inc. has a 1-year low of $12.97 and a 1-year high of $31.77. The company has a market cap of $3.20 billion, a P/E ratio of -852.38 and a beta of 1.52.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%.The business had revenue of $105.40 million for the quarter, compared to analyst estimates of $103.68 million. As a group, analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.15 EPS for the current year.

Insiders Place Their Bets

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 3,172 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $23.61, for a total transaction of $74,890.92. Following the completion of the sale, the insider directly owned 720,755 shares in the company, valued at approximately $17,017,025.55. This trade represents a 0.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Latha Vairavan sold 1,341 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $23.61, for a total value of $31,661.01. Following the sale, the chief financial officer owned 86,413 shares of the company’s stock, valued at approximately $2,040,210.93. The trade was a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 31,254 shares of company stock valued at $732,019. 9.40% of the stock is currently owned by insiders.

Arcutis Biotherapeutics Company Profile

(Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.